Originally published as JCO Early Release 10.1200/JCO.2003.08.054 on September 8 2003

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bierman, P. J. Articles by Goldstone, A. Search for Related Content PubMed PubMed Citation Articles by Bierman, P. J. Articles by Goldstone, A. Social Bookmarking                            What's this?

Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin’s Lymphoma: A Comparison With Allogeneic and Autologous Transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

From the University of Nebraska Medical Center, Omaha, NE; University of Colorado Health Sciences Center, Denver, CO; International Bone Marrow Transplant Registry, Milwaukee, WI; University College Hospital, London, United Kingdom; Ireland Cancer Center, Cleveland, OH; Christian Albrechts University, Kiel, Germany; and University of Chicago, Chicago, IL.

Address reprint requests to Philip J. Bierman, MD, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680; e-mail: pjbierma{at}unmc.edu.

Purpose: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma (NHL).

Patients and Methods: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants.

Results: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P = .008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P = .0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P = .003) and overall survival (P = .04) when compared with patients who received unpurged autografts.

Conclusion: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Foster, D. A. Gabriel, and T. Shea Role of Hematopoietic Stem Cell Transplant in the Management of Follicular Lymphoma Oncologist, July 1, 2009; 14(7): 726 - 738. [Abstract] [Full Text] [PDF]

				S. Quijano, A. Lopez, J. Manuel Sancho, C. Panizo, G. Deben, C. Castilla, J. Antonio Garcia-Vela, A. Salar, N. Alonso-Vence, E. Gonzalez-Barca, et al. Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry J. Clin. Oncol., March 20, 2009; 27(9): 1462 - 1469. [Abstract] [Full Text] [PDF]

				K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF]

				H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF]

				M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation Ann. Onc., November 1, 2008; 19(11): 1935 - 1940. [Abstract] [Full Text] [PDF]

				I. F. Khouri Response: Choice of conditioning for allogeneic transplantation in follicular lymphoma: nonmyeloablative or high-dose chemotherapy? Blood, September 15, 2008; 112(6): 2586 - 2587. [Full Text] [PDF]

				S. Mackinnon Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337. [Abstract] [Full Text] [PDF]

				M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF]

				N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF]

				J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF]

				H. C. Fung, M. A. Higman, and K. van Besien Stem cell transplantation ASH Self-Assessment Program, January 1, 2007; 2007(1): 328 - 360. [Full Text] [PDF]

				R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 Blood, April 15, 2006; 107(8): 3205 - 3211. [Abstract] [Full Text] [PDF]

				A. K. Ganti, P. J. Bierman, J. C. Lynch, R. G. Bociek, J. M. Vose, and J. O. Armitage Hematopoietic stem cell transplantation in mantle cell lymphoma Ann. Onc., April 1, 2005; 16(4): 618 - 624. [Abstract] [Full Text] [PDF]

				A. Craiu, Y. Saito, A. Limon, H. M. Eppich, D. P. Olson, N. Rodrigues, G. B. Adams, D. Dombkowski, P. Richardson, R. Schlossman, et al. Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function Blood, March 1, 2005; 105(5): 2235 - 2238. [Abstract] [Full Text] [PDF]

				J. W. Sweetenham Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease Hematology, January 1, 2005; 2005(1): 252 - 259. [Abstract] [Full Text] [PDF]

				C. O. Freytes, F. R. Loberiza, J. D. Rizzo, A. Bashey, C. N. Bredeson, M. S. Cairo, R. P. Gale, M. M. Horowitz, T. R. Klumpp, R. Martino, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry Blood, December 1, 2004; 104(12): 3797 - 3803. [Abstract] [Full Text] [PDF]

				J. N. Winter, R. D. Gascoyne, and K. Van Besien Low-Grade Lymphoma Hematology, January 1, 2004; 2004(1): 203 - 220. [Abstract] [Full Text] [PDF]

				M. R. Bishop The Graft-Versus-Lymphoma Effect: Fact, Fiction, or Opportunity? J. Clin. Oncol., October 15, 2003; 21(20): 3713 - 3715. [Full Text] [PDF]